SAGE News and Press, Sage Therapeutics Inc. From 07/26/23

2023-07-26 13:36:56 ET Sage Therapeutics ( NASDAQ: SAGE ) lost more than 14% Wednesday to reach the lowest level since November amid investor concerns over its depression therapy, zuranolone, as the FDA is set to decide on its marketing application by early August. In March,...

2023-07-26 10:37:58 ET Gainers: ABVC BioPharma ( ABVC ) +50% . Benitec Biopharma ( BNTC ) +45% . Tilray Brands ( TLRY ) +23% . Teladoc Health ( TDOC ) +21% . Biodexa Pharmaceuticals ( BDRX ) +8% . Losers: Carmell Ther...

2023-07-25 08:26:12 ET Biogen ( NASDAQ: BIIB ) exceeded Wall Street forecasts with its Q2 2023 results on Tuesday and announced a new cost savings program including plans to reduce about 1,000 employees as the company shifts its resources to newly approved medications. The C...

2023-07-16 12:00:00 ET While investors are bracing for yet another challenging quarter when earnings season kicks off for commercial-stage biopharma later this month, Barclays has picked Eli Lilly ( NYSE: LLY ) and Merck ( NYSE: MRK ) as two of the most favorably positioned ...

2023-06-30 13:15:02 ET Summary Sage Therapeutics, Inc. should find out in August whether its drug targeting major depressive disorder and postpartum depression, zuranolone, will be approved. Zuranolone is being co-developed with Biogen, who made an upfront payment to Sage of $1.5b...

Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, announced today that the Company will participate in a fireside chat at the Goldman Sachs 44 th Annual Global Healthcare Conference on Monday, June 12, 2023, at 11:2...

2023-05-09 05:56:59 ET Summary PDUFA date of August 5, 2023, was established to review zuranolone for the treatment of patients with major depressive disorder and postpartum depression. Biogen is a partner who is helping Sage advance zuranolone for the treatment of patients with M...

2023-05-02 15:28:08 ET Sage Therapeutics, Inc. (SAGE) Q1 2023 Earnings Conference Call May 02, 2023, 08:00 AM ET Company Participants Helen Rubinstein - Director of Investor Relations Barry Greene - Chief Executive Officer Jim Doherty - Chief Development Officer ...

2023-05-02 06:38:28 ET Sage Therapeutics press release ( NASDAQ: SAGE ): Q1 GAAP EPS of -$2.46 beats by $0.06 . Revenue of $3.3M (+108.9% Y/Y) beats by $1.02M . Cash Position: Cash, cash equivalents and marketable securities as of March 31, 2023 were $1.1 billi...

New Drug Application (NDA) for zuranolone in the treatment of Major Depressive Disorder (MDD) and Postpartum Depression (PPD) under priority review by U.S. Food and Drug Administration (FDA) with a PDUFA date of August 5, 2023 Sage and Biogen progressing key commercial preparation...